Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Moderate to Severe Atopic Dermatitis
NCT05197023Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing SHR-1819 injection with placebo (2 arms). Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events. Started Jan 2022; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05197023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197023.